Avita Medical Ltd. (ASX: AVH) (OTC: AVMXF) (OTCQX:AVMXY), the regenerative medicine company, today announced a free issuance period through the Bank of New York Mellon whereby AVMXF shareholders may bundle their shares into American Depository Receipts (ADRs) to trade under the AVMXY symbol. The bundling fee will be waived by the Bank of New York Mellon for the three-month period starting June 11, 2012 and ending on September 11, 2012.

Avita Medical trades its ordinary shares on the Australian Stock Exchange under the AVH symbol. The AVMXF shares represent ordinary Australian shares that have been settled in US dollars. Each AVMXY ADR consists of a bundle of 20 ordinary shares.

Conversion of AVMXF shares allows US investors to freely trade ADRs, thereby avoiding the costs and complexities, including currency exchange fluctuations, involved in buying shares on foreign exchanges.

“This is an excellent opportunity for our U.S. investors to bundle their AVMXF shares into AVMXY ADRs, for which we anticipate increased trading volume over time,” said William Dolphin, Ph.D., CEO of Avita Medical. “BNY Mellon has graciously offered to waive the bundling fee for our shareholders for a three month period. We encourage all interested AVMXF shareholders to visit our website or contact BNY Mellon to take advantage of this opportunity.”

Investors holding AVMXF shares who are interested in bundling their shares into the AVMXY ADRs should contact the Company’s transfer agent, Bank of New York Mellon (“BNY Mellon”):

Kristen ReschBank of New York Mellon Depository Receipts+1-212-815-2213kirsten.resch@bnymellon.com


Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The company’s lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

Avita Medical (PK) (USOTC:AVMXF)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Avita Medical (PK) Charts.
Avita Medical (PK) (USOTC:AVMXF)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Avita Medical (PK) Charts.